Related Experiment Video
Updated: Oct 1, 2025
Intracranial Injection of Adeno-associated Viral Vectors
Published on: November 17, 2010
Tumefactive Demyelinating Brain Lesion Developing after Administration of Adenovector-Based COVID-19 Vaccine: A Case
Ravindra K Garg1, Hardeep S Malhotra1, Neeraj Kumar1
1Department of Neurology, King George Medical University, Lucknow, Uttar Pradesh, India.
Background:
Postmarketing surveillance of COVID-19 vaccination reveals that the COVID-19 vaccine administration is associated with several rare but serious neurological complications.
Case Report:
We report a case of new-onset tumefactive demyelinating brain lesion that developed after administration of an adenovector-based COVID-19 vaccine. A middle-aged female presented with recent right hemiparesis, which was noticed 2 days after she received the first dose of the vaccine. Magnetic resonance imaging (MRI) revealed a large subcortical T2/FLAIR hyperintensities involving corpus callosum as well. The patient responded to oral methylprednisolone. At 4 weeks, a follow-up MRI revealed a reduction in size of the lesion.
Conclusion:
To conclude, adenovector-based COVID-19 vaccination may be associated with a tumefactive demyelinating lesion.
